Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer

Howard I. Scher, David Kelsen, Leonard Kalman, Larry Jones, Joseph Burchenal, Richard Gralla

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


A phase-II trial of the second-generation platinum analog 1,2-diaminocyclohexane (4-carboxyphalato) platinum (II) (DACCP) was performed in 33 patients with non-small cell lung cancer. The compound was studied because of its lack of cross resistance in vitro and decreased nephrotoxicity in both preclinical testing and in a phase-I trial. The starting dose was 640 mg/m2 IV every 3 weeks, with escalations to 720 mg/m2 in the absence of toxicity. Myelosuppression and nephrotoxicity were uncommon. Allergic reactions and neurotoxicity were seen in five and three patients, respectively. Of 28 patients evaluable for response, one partial remission of 3 months' duration was noted in a patient who had previously responded but subsequently progressed during cisplatin and vindesine medication. No responses were seen in 11 adequately treated patients who had received no prior therapy. DACCP has only minimal activity in non-small cell lung cancer. No further studies are planned in this disease.

Original languageEnglish (US)
Pages (from-to)101-103
Number of pages3
JournalCancer Chemotherapy and Pharmacology
Issue number2
StatePublished - Feb 1984
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this